Lyell Immunopharma, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
LYEL$16.75+8.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| Net loss | $(114,437) | $(133,725) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 13,341 | 16,260 |
| Depreciation and amortization expense | 6,608 | 9,142 |
| (Gain) loss on securities purchase agreement put/call | (17,561) | 4,029 |
| Non-cash lease income | (3,569) | (2,511) |
| Net amortization and accretion on marketable securities | (2,410) | (3,899) |
| Change in fair value of success payment liabilities | (1,015) | 221 |
| Loss on property and equipment disposals, net | 117 | 3,510 |
| Change in fair value of contingent consideration payable | — | (1,706) |
| Impairment of long-lived assets | — | 1,443 |
| Loss on marketable equity security | — | 29 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, other current assets and other assets | 3,589 | 5,216 |
| Accounts payable | 1,063 | (2,664) |
| Accrued liabilities and other current liabilities | 7,245 | (12,546) |
| Other non-current liabilities | 30 | (572) |
| Net cash used in operating activities | (106,999) | (117,773) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Purchases of property and equipment | (411) | (476) |
| Sales of property and equipment | 5 | 263 |
| Purchases of marketable securities | (134,290) | (236,099) |
| Maturities of marketable securities | 221,284 | 321,774 |
| Net cash provided by investing activities | 86,588 | 85,462 |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from securities purchase agreement equity issuance | 50,000 | 50,000 |
| Proceeds from employee stock purchase plan | 522 | 184 |
| Proceeds from exercise of stock options | 67 | — |
| Proceeds from at-the-market offering, net of offering expenses | 1,696 | — |
| Net cash provided by financing activities | 52,285 | 50,184 |
| Net increase in cash, cash equivalents and restricted cash | 31,874 | 17,873 |
| Cash, cash equivalents and restricted cash at beginning of period | 61,766 | 107,287 |
| Cash, cash equivalents and restricted cash at end of period | $93,640 | $125,160 |
| Represented by: | ||
| Cash and cash equivalents | $92,053 | $123,575 |
| Restricted cash | 1,587 | 1,585 |
| Total | $93,640 | $125,160 |
| SUPPLEMENTAL CASH FLOW INFORMATION | ||
| Cash paid for amounts included in the measurement of lease liabilities | $9,698 | $9,419 |
| Non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $79 | $— |
| Securities purchase agreement put/call issuance | $— | $7,774 |
| Equity issued for contingent consideration - ImmPACT Bio USA Inc. acquisition | $— | $5,894 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.